| CAS NO: | 475-31-0 |
| 包装 | 价格(元) |
| 10 mM * 1 mL in DMSO | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 500mg | 电议 |
| 1 g | 电议 |
| 5 g | 电议 |
| 生物活性 | Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1]. | ||||||||||||||||
| IC50& Target[1] |
| ||||||||||||||||
| 体外研究 (In Vitro) | Glycocholic acid (GC) increases the cytotoxicity of epirubicin, significantly increases the intracellular accumulation of epirubicin in Caco-2 cells and the absorption of epirubicin in rat small intestine, and intensified epirubicin-induced apoptosis. Glycocholic acid and epirubicin significantly reduce mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulate the MDR1 promoter region; suppress the mRNA expression of Bcl-2; induce the mRNA expression of Bax; and significantly increase the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3. A combination of anticancer drugs with Glycocholic acid can control MDR via a mechanism that involves modulating P-gp and MRPs as well as regulating apoptosis-related pathways[1]. | ||||||||||||||||
| Clinical Trial | |||||||||||||||||
| 分子量 | 465.62 | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| Formula | C26H43NO6 | ||||||||||||||||
| CAS 号 | 475-31-0 | ||||||||||||||||
| 结构分类 |
| ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
| ||||||||||||||||
| 溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(214.77 mM) H2O :< 0.1 mg/mL (ultrasonic;warming;heat to 60℃)(insoluble) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
